子宮内膜がん治療市場：治療法、グレード、エンドユーザー別-2025-2030年の世界予測

子宮内膜がん治療市場の2023年の市場規模は84億2,000万米ドルで、2024年には88億7,000万米ドルに達すると予測され、CAGR 5.47％で成長し、2030年には122億3,000万米ドルに達すると予測されています。

子宮内膜がん治療市場は、罹患率の増加、医療技術の進歩、疾患に対する理解の深まりに応じて進化し続けています。子宮内膜がんは、主に子宮内膜を侵し、最も一般的な婦人科悪性腫瘍の一つです。効果的な治療法の必要性は、高齢化人口の増加と肥満率の上昇によって強調されています。治療には外科的介入、放射線療法、ホルモン療法、化学療法が含まれ、生存率と患者のQOLの向上を目標としています。エンドユーザーには、病院、診療所、革新的な治療アプローチに注力する研究機関が含まれます。市場の成長は、個別化医療や免疫療法の進展、がん研究への資金提供の増加の影響を受けています。早期発見と治療成績を大幅に向上させる標的療法と非侵襲的診断ツールの開発にはビジネスチャンスがあります。さらに、製薬会社と研究機関のコラボレーションは、技術革新のペースを加速させることができます。しかし、高額な治療費、潜在的な副作用、厳しい規制要件といった制約が課題となっています。さらに、ヘルスケアへのアクセスにおける世界の格差は、市場の成長を制限する可能性があります。このような課題にもかかわらず、市場はバイオマーカー研究の革新に大きな機会を提供し、診断と治療計画の精度を高めています。市場の競争は激しく、大手製薬企業や新興バイオテクノロジー企業が研究開発投資に注力しています。主な提言としては、研究協力のためのパートナーシップの活用、研究開発のための新技術プラットフォームへの投資、患者アクセスを改善するための費用対効果への取り組みなどがあります。先進的なゲノムおよび分子プロファイリングにおける革新が、子宮内膜がん治療の将来を形作る可能性が高く、患者の転帰とヘルスケア提供を再定義する画期的な治療法を導入する可能性を提供します。

市場力学：急速に進化する子宮内膜がん治療市場の主要市場インサイトを公開

子宮内膜がん治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の1型および2型子宮内膜がんの蔓延
  • 子宮内膜がん治療採用を拡大する政府の取り組み
  • 個別化・標的化子宮体がん治療の出現
• 市場抑制要因
  • 子宮内膜治療に対する限られた償還構造
• 市場機会
  • 新規の子宮内膜がん治療法を開発するための継続的な研究活動
  • 子宮内膜がん治療薬に対する有利な政府承認
• 市場の課題
  • 特定の治療に関連する規制上のハードルとリスク

ポーターのファイブフォース：子宮内膜がん治療市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：子宮内膜がん治療市場における外部からの影響の把握

外部マクロ環境要因は、子宮内膜がん治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析子宮内膜がん治療市場における競合情勢の把握

子宮内膜がん治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス子宮内膜がん治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、子宮内膜がん治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨子宮内膜がん治療市場における成功への道筋を描く

子宮内膜がん治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 全世界におけるタイプ1およびタイプ2子宮内膜がんの有病率
    • 子宮内膜がん治療の採用拡大に向けた政府の取り組み
    • 個別化・標的化された子宮がん治療の出現
  • 抑制要因
    • 子宮内膜治療に対する限定的な償還構造
  • 機会
    • 子宮内膜がんの新たな治療法の開発に向けた継続的な調査活動
    • 子宮内膜がん治療薬に対する政府の好意的な承認
  • 課題
    • 特定の治療に伴う規制上のハードルとリスク
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 子宮内膜がん治療市場治療別

• 化学療法
• 免疫療法
• 放射線治療

第7章 子宮内膜がん治療市場：グレード別

• タイプI
• タイプ II

第8章 子宮内膜がん治療市場：エンドユーザー別

• 外来手術センター
• がんセンター
• 病院・クリニック

第9章 南北アメリカの子宮内膜がん治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の子宮内膜がん治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの子宮内膜がん治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AstraZeneca PLC
• Bayer AG
• Becton, Dickinson and Company
• Boston Scientific Corporation
• Bristol-Myers Squibb Company
• Celgene Corporation
• Context Therapeutics Inc.
• CooperSurgical Inc.
• Eisai Co., Ltd.
• Elekta AB
• F. Hoffmann-La Roche AG
• General Electric Company
• GlaxoSmithKline PLC
• Hologic Inc.
• Johnson & Johnson Services, Inc.
• Karyopharm Therapeutics Inc.
• Koninklijke Philips N.V.
• LiNA Medical ApS
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Siemens Healthineers AG
• Takeda Pharmaceutical Company Limited

LIST OF FIGURES

• FIGURE 1. ENDOMETRIAL CANCER TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ENDOMETRIAL CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. ENDOMETRIAL CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ENDOMETRIAL CANCER TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ENDOMETRIAL CANCER TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYPE I, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYPE II, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 28. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 29. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 30. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 45. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 46. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 47. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. INDIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 49. INDIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 50. INDIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 101. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 102. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. POLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 113. POLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 114. POLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. QATAR ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 116. QATAR ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 117. QATAR ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. ENDOMETRIAL CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 146. ENDOMETRIAL CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Endometrial Cancer Treatment Market was valued at USD 8.42 billion in 2023, expected to reach USD 8.87 billion in 2024, and is projected to grow at a CAGR of 5.47%, to USD 12.23 billion by 2030.

The market for endometrial cancer treatment continues to evolve in response to increasing incidence rates, advancements in medical technology, and a deeper understanding of the disease. Endometrial cancer primarily affects the lining of the uterus and is one of the most common gynecological malignancies. The necessity for effective treatments is underscored by a growing aging population and rising obesity rates, both of which contribute to higher susceptibility. Treatment encompasses surgical interventions, radiation, hormone therapies, and chemotherapy, targeted towards improving survival rates and patients' quality of life. The end-users include hospitals, clinics, and research institutions focusing on innovative therapeutic approaches. Market growth is influenced by ongoing advancements in personalized medicine and immunotherapy, as well as increased funding for cancer research. Opportunities lie in the development of targeted therapies and non-invasive diagnostic tools, which can significantly boost early detection and treatment outcomes. Moreover, collaborations between pharmaceutical companies and research institutions can accelerate the pace of innovation. However, limitations such as high treatment costs, potential side effects, and stringent regulatory requirements pose challenges. Furthermore, disparities in healthcare access globally can restrict market growth. Despite these challenges, the market offers robust opportunities for innovation in biomarker research, enhancing the precision of diagnosis and treatment plans. The nature of the market is highly competitive, driven by major pharmaceutical companies and emerging biotech firms focusing on R&D investments. Key recommendations include leveraging partnerships for research collaborations, investing in new technology platforms for drug development, and addressing cost-effectiveness to improve patient access. Innovations in advanced genomic and molecular profiling will likely shape the future of endometrial cancer treatment, offering the potential to introduce groundbreaking therapies that can redefine patient outcomes and healthcare delivery.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Endometrial Cancer Treatment Market

The Endometrial Cancer Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevelance of type 1 and type 2 endometrial cancer worldwide
  • Government initiatives to expand endometrial cancer treatment adoption
  • Emergence of personalized and targeted uterine cancer therapy
• Market Restraints
  • Limited reimbursement structure for endometrial treatment
• Market Opportunities
  • Ongoing research activities to develop novel endometrial cancer treatments
  • Favorable government approvals for endometrial cancer drugs
• Market Challenges
  • Regulatory hurdles and risk associated with certain treatment

Porter's Five Forces: A Strategic Tool for Navigating the Endometrial Cancer Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Endometrial Cancer Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Endometrial Cancer Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Endometrial Cancer Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Endometrial Cancer Treatment Market

A detailed market share analysis in the Endometrial Cancer Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Endometrial Cancer Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Endometrial Cancer Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Endometrial Cancer Treatment Market

A strategic analysis of the Endometrial Cancer Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Endometrial Cancer Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca PLC, Bayer AG, Becton, Dickinson and Company, Boston Scientific Corporation, Bristol-Myers Squibb Company, Celgene Corporation, Context Therapeutics Inc., CooperSurgical Inc., Eisai Co., Ltd., Elekta AB, F. Hoffmann-La Roche AG, General Electric Company, GlaxoSmithKline PLC, Hologic Inc., Johnson & Johnson Services, Inc., Karyopharm Therapeutics Inc., Koninklijke Philips N.V., LiNA Medical ApS, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Siemens Healthineers AG, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Endometrial Cancer Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Treatment, market is studied across Chemotherapy, Immunotherapy, and Radiation Therapy.
• Based on Grade, market is studied across Type I and Type II.
• Based on End-User, market is studied across Ambulatory Surgical Centers, Cancer Centers, and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevelance of type 1 and type 2 endometrial cancer worldwide
    • 5.1.1.2. Government initiatives to expand endometrial cancer treatment adoption
    • 5.1.1.3. Emergence of personalized and targeted uterine cancer therapy
  • 5.1.2. Restraints
    • 5.1.2.1. Limited reimbursement structure for endometrial treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing research activities to develop novel endometrial cancer treatments
    • 5.1.3.2. Favorable government approvals for endometrial cancer drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Regulatory hurdles and risk associated with certain treatment
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Endometrial Cancer Treatment Market, by Treatment

• 6.1. Introduction
• 6.2. Chemotherapy
• 6.3. Immunotherapy
• 6.4. Radiation Therapy

7. Endometrial Cancer Treatment Market, by Grade

• 7.1. Introduction
• 7.2. Type I
• 7.3. Type II

8. Endometrial Cancer Treatment Market, by End-User

• 8.1. Introduction
• 8.2. Ambulatory Surgical Centers
• 8.3. Cancer Centers
• 8.4. Hospitals & Clinics

9. Americas Endometrial Cancer Treatment Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Endometrial Cancer Treatment Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Endometrial Cancer Treatment Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AstraZeneca PLC
• 3. Bayer AG
• 4. Becton, Dickinson and Company
• 5. Boston Scientific Corporation
• 6. Bristol-Myers Squibb Company
• 7. Celgene Corporation
• 8. Context Therapeutics Inc.
• 9. CooperSurgical Inc.
• 10. Eisai Co., Ltd.
• 11. Elekta AB
• 12. F. Hoffmann-La Roche AG
• 13. General Electric Company
• 14. GlaxoSmithKline PLC
• 15. Hologic Inc.
• 16. Johnson & Johnson Services, Inc.
• 17. Karyopharm Therapeutics Inc.
• 18. Koninklijke Philips N.V.
• 19. LiNA Medical ApS
• 20. Merck & Co., Inc.
• 21. Novartis AG
• 22. Pfizer Inc.
• 23. Sanofi S.A.
• 24. Siemens Healthineers AG
• 25. Takeda Pharmaceutical Company Limited